LTOT

Long-Term Oxygen Therapy (LTOT) is a medical treatment that delivers supplemental oxygen to individuals with chronic lung disease and persistent low blood oxygen levels. It aims to maintain adequate arterial oxygenation during rest and activity when hypoxemia would otherwise limit health and quality of life. LTOT is typically prescribed for at least 15 hours per day, with many patients using it around the day’s full duration.

Indications and criteria vary by guideline, but the strongest evidence base is for chronic obstructive pulmonary disease (COPD) with resting arterial oxygen tension (PaO2) of 55 mmHg or less, or arterial oxygen saturation (SaO2) of 88% or less on room air. Patients with PaO2 between 56 and 59 mmHg or SaO2 up to 89% who have signs of ongoing hypoxemia—such as polycythemia, pulmonary hypertension, or right heart strain—may also qualify. LTOT can also benefit select patients with other chronic hypoxemic lung diseases, including interstitial lung disease, pulmonary fibrosis, and cystic fibrosis, when hypoxemia is documented.

Delivery methods include stationary oxygen concentrators, portable concentrators, and compressed gas cylinders, typically administered via nasal cannula or face mask. Flow rates are individualized and commonly range from about 1 to 4 liters per minute for nasal cannulas, with higher settings used as needed.

Outcomes and safety: LTOT in hypoxemic COPD improves survival and may enhance quality of life and exercise tolerance, though effects vary by patient. It is not beneficial for normoxemic individuals. Regular monitoring by clinicians, oxygen saturation or blood gas assessments, and device maintenance are essential. Safety considerations include strict avoidance of smoking or open flames near oxygen and proper handling of equipment to prevent leaks.